ABR
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
American Pacific Borates Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π Esg
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
1
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
American Pacific Borates Limited
π Performance
Price History
+1161.90%
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$2.65
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in ABR
0
π Total Capital Earnings
N/A
π Average investment frequency
27 weeks
π΅ Average investment amount
$491
β° Last time a customer invested in ABR
1027 days
ABR investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in ABR also invest in...
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
12.86%
π Share price
$129.54 AUD
π GLOBAL
β³οΈ DIVERSIFIED
π€ TECHNOLOGY
π HIGH PRICE GROWTH
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
π Performance (5Yr p.a)
13.00%
π Share price
$15.13 AUD
π¦πΊ EX AUSTRALIA
π HIGH PRICE GROWTH
β³οΈ DIVERSIFIED
π€ TECHNOLOGY
Classic Minerals Ltd. engages in exploration of mineral resource-based projects, focusing on gold and nickel. The company is headquartered in Perth, Western Australia. The company went IPO on 2013-05-24. The firm holds approximately 578 square kilometers of tenements across two regional exploration areas in minerals-rich West Australia. The company is focused on gold deposits in Western Australia's Goldfields region at Forrestania and Kat Gap. Its flagship Kat Gap Gold Project is located approximately 170 kilometers (km) south of Southern Cross and also 50 km south of the Company's Forrestania Gold Project. The Forrestania Gold Project is located approximately 120 km south of Southern Cross, Western Australia and contains the Lady Ada and Lady Magdalene deposits. Its Fraser Range Project (E28/1904) is approximately 40 km to the northeast of Sirius Nova deposit on the Fraser-Albany Mobile Belt, approximately 160 km east southeast of Kambalda and is of interpreted Proterozoic age. The company holds approximately 28 km of strike across 84 square kilometers.
π Performance (5Yr p.a)
-13.08%
π Share price
$0.00 AUD
βοΈ MINING
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyβs immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
π Performance (5Yr p.a)
20.87%
π Share price
$0.05 AUD
𧬠BIOTECHNOLOGY
π HIGH PRICE GROWTH
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
3.71%
π Share price
$66.50 AUD
π GLOBAL
β³οΈ DIVERSIFIED